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Abstract
The MELAS syndrome (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes) is most commonly
caused by the 3243ACG mutation in mitochondrial DNA, resulting in impaired mitochondrial protein synthesis and
decreased activities of the respiratory chain complexes. These defects may cause a reduced capacity for ATP synthesis and an
increased rate of production of reactive oxygen species. Myoblasts cultured from controls and patients carrying the
3243ACG mutation were used to measure ATP, ADP, catalase and superoxide dismutase, which was also measured from
blood samples. ATP and ADP concentrations were decreased in myoblasts with the 3243ACG mutation, but the ATP/ADP
ratio remained constant, suggesting a decrease in the adenylate pool. The superoxide dismutase and catalase activities were
higher than in control cells, and superoxide dismutase activity was slightly, but not significantly higher in the blood of
patients with the mutation than in controls. We conclude that impairment of mitochondrial ATP production in myoblasts
carrying the 3243ACG mutation results in adenylate catabolism, causing a decrease in the total adenylate pool. The increase
in superoxide dismutase and catalase activities could be an adaptive response to increased production of reactive oxygen
species due to dysfunction of the mitochondrial respiratory chain. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
The classical clinical phenotype of MELAS syn-
drome includes encephalomyopathy, lactic acidosis
and stroke-like episodes [1], but multiorgan involve-
ment and phenotypic variability are also character-
istic of this disease [2]. The 3243ACG mutation in
mitochondrial DNA, which is the most common
cause of the MELAS syndrome [3], has been previ-
ously shown to result in impairment of transcription
termination [4] and protein synthesis [5], and the
most common biochemical consequence of the muta-
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tion is a decrease in the activities of respiratory chain
complexes I and IV [6^8]. Decreased production of
ATP has been suggested as a major pathophysiolog-
ical phenomenon in mitochondrial diseases and in
the MELAS syndrome [9], this being supported by
the demonstration of mitochondrial myopathy in ad-
enine nucleotide translocator (Ant1, heart/muscle
isoform) knock-out mice [10]. No decrease has been
observed in ATP production in cultured ¢broblasts
with the 3243ACG mutation [11,12], but the situa-
tion may be di¡erent in cells derived from tissues
that have a higher energy demand and are a¡ected
in mitochondrial myopathies.
The production of oxygen-derived free radicals
may have a signi¢cant role in the pathophysiology
of neurodegenerative diseases [13,14] and mitochon-
drial diseases. Partial reduction of oxygen results in
the formation of reactive oxygen species (ROS), in-
cluding superoxide (O32 ), peroxide (O
23
2 ) and hy-
droxyl radicals (OH). There are several possible sites
of cellular superoxide formation, including complex I
[15] and complex III [16] of the mitochondrial respi-
ratory chain. Mammalian cells have several defence
mechanisms for use against attacks by these toxic
oxygen radicals. The mitochondrial superoxide dis-
mutase (manganese SOD) and cytosolic superoxide
dismutase (copper/zinc SOD) catalyse the conversion
of superoxide to hydrogen peroxide, which is de-
graded by catalase in peroxisomes and glutathione
peroxidase in the cytosol and mitochondria. Cells
carrying mtDNA mutations have been observed to
be more sensitive to oxygen stress than control cells
[17]. Furthermore, a higher rate of peroxide produc-
tion and an increased rate of apoptosis have been
reported in the presence of high oxygen concentra-
tions in cybrids carrying the 3243ACG mutation
[18].
The purpose of this study was to examine the
pathophysiological consequences of the oxidative
phosphorylation defect caused by the 3243ACG
mutation by determining the concentrations of
high energy phosphates and the activities of ROS
scavenging enzymes in cultured myoblasts. ATP
and ADP were measured to obtain an estimate of
the cellular energy state and the adenylate pool in
myoblasts. The superoxide dismutase and catalase
activities were also measured, as it has been sug-
gested that an increase in the activity of superoxide
dismutase may indicate increased free radical forma-
tion [19].
2. Materials and methods
2.1. Muscle cell culture
The study was approved by the Ethical Committee
of the Medical Faculty of the University of Oulu and
informed consent was obtained from the patients.
Myoblast cell cultures (Me1, Me4, Me5 and Me8)
were established from four patients (P1, P4, P5 and
P8, respectively) with the 3243ACG mutation in
their mtDNA and from four controls (Co1^Co4).
Eligible controls were under 50 years of age and
without any chronic diseases. The muscle samples
obtained from the patients and controls were ¢rst
dissected free of any visible connective tissue and
cut into 1 mm diameter pieces, which were plated
and grown for 2^3 weeks in Earle’s minimum essen-
tial medium (Sigma, St. Louis, MO, USA) contain-
ing 15% foetal bovine serum, 4 mM L-glutamine,
1 mM pyruvate, amphotericin B (0.25 Wg/ml), strep-
tomycin (100 Wg/ml) and penicillin (100 U/ml). The
cells were detached with trypsin-EDTA and pre-
plated for 10 min in order to remove possible con-
taminating ¢broblasts. The medium was then trans-
ferred to new culture dishes (Nunclon, NalceNunc,
Roskilde, Denmark). Con£uent cells were washed
with phosphate-bu¡ered saline (PBS), detached with
trypsin-EDTA (Sigma), divided and inoculated into
two new dishes. The cell cultures were used in pas-
sages three to seven in all experiments.
2.2. Blood samples
Blood samples were obtained from 17 patients
with the 3243ACG mutation (age 45 þ 15 years,
mean þ S.D.) and from 13 controls (age 50 þ 11
years, mean þ S.D.). Haemoglobin concentration
and SOD activity were measured immediately.
2.3. High energy phosphates
HClO4 was added to the cell cultures for the me-
tabolite assays. The cells were scraped with a rubber
policeman and the cell suspension was sonicated and
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neutralised with K2CO3-triethanolamine. The soni-
cated cells were centrifuged for 10 min at 3200Ug
and the protein concentration in the pellet was
measured. ATP was measured spectrophotometri-
cally by detecting NADPH formation in the reac-
tions catalysed by hexokinase and glucose 6-phos-
phate dehydrogenase [20]. ADP was measured by
pyruvate kinase and lactate dehydrogenase and the
decrease in absorbance of NADH was measured
spectrophotometrically at 340 nm minus 385 nm
with an Aminco DW-2 dual wavelength spectropho-
tometer [21].
2.4. Determination of mutant heteroplasmy
The cells were scraped from the culture dishes with
a rubber policeman and total DNA was extracted
with the QIAamp Blood Kit (Qiagen, CA, USA).
The degree of 3243ACG mutant heteroplasmy was
measured in samples from three or four passages of
each cell line cultured in parallel to those used in
experiments [22]. The degrees of the mutant hetero-
plasmy in the muscle samples from the patients were
also determined.
2.5. Superoxide dismutase and catalase activities
Cells were scraped from culture dishes with a rub-
ber policeman, dissolved in potassium phosphate
bu¡er (pH 7.0) and sonicated on ice. Soluble proteins
were quanti¢ed spectrophotometrically by a dye
binding assay (Bio-Rad protein assay, Bio-Rad Lab-
oratories, Hercules, CA, USA).
Total superoxide dismutase activity was measured
from myoblast cell lysate and from blood cells by a
method which employs xanthine and xanthine oxi-
dase to generate superoxide radicals, which react
with 2-(4-iodophenyl)-3-(4-nitrophenol)-5-phenylte-
trazolium chloride to form a red formazan dye meas-
urable spectrophotometrically at 505 nm (Ransod
kit, Randox Ltd., Antrim, UK) [23]. Superoxide dis-
mutase activity was measured in terms of the inhib-
ition of formazan formation. The inhibition levels
were converted to SOD units using a standard curve,
prepared with SOD standards provided by the man-
ufacturer.
Catalase activity was measured from sonicated
myoblast lysate. Degradation of hydrogen peroxide
was detected spectrophotometrically at 240 nm as
previously described [24]. Catalase activity was ex-
pressed as a ¢rst-order constant per unit of soluble
protein (mg31 s31 ml).
The statistical signi¢cances of di¡erences were cal-
culated using Student’s two-tailed t-test.
3. Results
3.1. Heteroplasmy
The clinical phenotypes of the patients with the
3243ACG mutation and the degrees of mutant het-
eroplasmy are shown in Table 1. It should be noted
that although the muscle sample from patient P4 had
a mutant heteroplasmy of 62%, the 3243ACG mu-
tation had disappeared in two out of the four myo-
blast culture dishes that were examined. Disappear-
ance of the mutant genome was not observed in any
other cell lines, but the degree of mutant hetero-
plasmy was lower in cultured myoblasts than in the
corresponding muscle samples. A similar decline of
mutant heteroplasmy has been previously observed
Table 1
Clinical features and myoblast cell lines of the patients with the 3243ACG mutation
Patient Cell line Sex Age Clinical phenotypea Degree of 3243ACG heteroplasmy (%)
in muscle in myoblasts
P1 Me1 F 50 Healthy 50 31 þ 9
P4 Me4 M 64 C D G H L M S 62 21 þ 19b
P5 Me5 F 40 B C E G L M S 80 41 þ 14
P8 Me8 F 55 C G 67 40 þ 19
aAbbreviations: B, basal ganglia calci¢cations; C, cognitive decline; D, diabetes mellitus; E, epilepsy; G, short stature; H, cardiac hy-
pertrophy; L, lactic acidosis ; M, clinical myopathy; S, sensorineural hearing impairment.
bTwo out of four cell lines had lost their mutant heteroplasmy. Data are means þ S.D. of three determinations.
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in cultured myoblasts with the 3243ACG mutation
[25].
3.2. Concentrations of high energy phosphates in
myoblasts
The ATP concentration (Table 2) was signi¢cantly
lower in Me4 (P6 0.002) and Me5 (P6 0.001) than
in two of the control cell lines, but was higher in the
Me1 cell line (P6 0.02) than in the controls. This is
explained by the low degree of mutant heteroplasmy
in the Me1 cells. Patient P1 was also clinically
healthy.
The total ADP concentration (Table 2) was signif-
icantly lower in Me4 (P6 0.02) than in the two rel-
evant control cell lines, but not in Me1 or Me5. The
ATP/ADP ratios (Table 2) did not di¡er signi¢cantly
between the control and MELAS myoblasts. The
total ATP+ADP pool (Table 2) was signi¢cantly
lower in Me4 (P6 0.001) and Me5 (P6 0.001) than
in the control cells, but higher in Me1 (P6 0.03).
3.3. Activities of antioxidant enzymes
Total superoxide dismutase activity was 644 þ 130
U/mg soluble protein in the control myoblasts, com-
pared with 819 þ 87, 924 þ 181 and 1033 þ 165 U/mg
soluble protein in Me4, Me5 and Me8, respectively
(Fig. 1). It was elevated in all the mutant cell lines
(Me4 P6 0.02, n = 7; Me5 P6 0.002, n = 7 and Me8
P6 0.001, n = 7) relative to the two control cell lines,
n = 14. Superoxide dismutase activity tended to be
slightly higher in the blood of patients with
3243ACG (Fig. 2) than that in the controls,
1186 þ 253 vs 1030 þ 242 U/mg soluble protein, re-
spectively, although the result did not reach statisti-
cal signi¢cance (P6 0.1).
Catalase activities in cultured myoblasts with
3243ACG were 3.4 þ 0.4, 10.1 þ 2.1 and 9.5 þ 2.6
U/mg soluble protein in Me4, Me5 and Me8, respec-
tively (Fig. 3), while the activity in the control cells
was 4.0 þ 1.4 U/mg soluble protein. Catalase activity
Fig. 1. Superoxide dismutase activities in cultured myoblasts. A
signi¢cant di¡erence compared with the controls is observed in
all cell lines with 3243ACG.
Fig. 2. Superoxide dismutase activity in blood cells of patients
with 3243ACG and controls. The solid lines of the boxes
show the 25%, 50% and 75% percentiles and dotted line repre-
sents the mean. The whiskers show the 5% and 95% percentiles.
Table 2
Concentrations of high energy phosphates in cultured myoblasts




ATP/ADP ratio ATP+ADP concentration
(nmol/mg soluble protein)
Controls 45.0 þ 10.0, n = 14 13.9 þ 8.1, n = 11 3.8 þ 1.8, n = 11 60.2 þ 11.0, n = 11
Me1 62.7 þ 20.5 18.7 þ 8.0 3.6 þ 1.3 81.4 þ 27.1
Me4 28.5 þ 10.7 5.7 þ 3.0 4.4 þ 1.4 34.2 þ 12.1
Me5 19.5 þ 4.6 9.5 þ 6.1 2.9 þ 2.1 29.0 þ 8.7
Data are means þ S.D. n is the number of cell culture dishes examined. For all cell lines with the 3243ACG mutation, n = 7.
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was signi¢cantly higher in cell lines Me5 (P6 0.001,
n = 7) and Me8 (P6 0.002, n = 7) than in the two
control cell lines (n = 14). The cell line Me4 did not
di¡er from the controls in this enzyme activity, how-
ever.
4. Discussion
Our results con¢rmed that the 3243ACG muta-
tion in mitochondrial DNA leads to impaired ATP
production in myoblasts. The impairment was more
severe in cell lines with a higher degree of mutant
heteroplasmy, whereas the ATP concentration was
not lowered in the cell line Me1 relative to the con-
trols. The normal biochemical phenotype in this cell
line suggests that the respiratory chain defect is not
severe enough to exceed the threshold at which de-
creased ATP production occurs and the MELAS
phenotype is expressed.
No di¡erence in ATP production has been found
between cultured MELAS and control ¢broblasts
[11,12], although decreased ATP concentrations
have been observed in ¢broblasts with the
3243ACG mutation after treatment with gramicidin
[11], a potassium ionophore which increases ATP
consumption. Gramicidin uncouples the mitochon-
dria and increases the workload of the plasma mem-
brane Na/K-ATPase. On the other hand, we
found a di¡erence in ATP production in nascent cul-
tured myoblasts that is most likely explained by the
high energy demand of muscle cells. Myoblasts are
an appropriate cell line to be used in metabolic stud-
ies of mitochondrial diseases, because resting energy
consumption is high and muscle cells are easily ma-
nipulated in cultures.
It is signi¢cant that the proportional changes in
cellular total ATP and ADP concentrations were
similar, so that the ATP/ADP ratio did not change.
If the ATP decrease were solely due to cellular de-
energisation, a corresponding ADP increase should
be observed. This was not the case, however, and
furthermore, the ADP concentration was signi¢-
cantly lower in the Me4 cell line than in the controls.
The free ADP concentration in muscle cells is very
low and most of it is bound to contractile proteins
[26], so that changes in the free ATP/ADP ratio have
only a small e¡ect on total ADP concentration. The
decrease in ADP with a concomitant decrease in
ATP can then only be accounted for by a loss of
adenine compounds from the cell. There is previous
evidence that complex I inhibition results in a rapid
decrease in the overall size of the adenine nucleotide
pool in nerve cell cultures [27], similar observations
have been documented in respiration-de¢cient ham-
ster ¢broblasts [28]. It has been proposed that the
activities of enzymes degrading AMP, adenylate de-
aminase and AMP nucleosidase, increase in condi-
tions where the adenylate energy charge is decreased
[29,30]. Furthermore, it is known that purine nucleo-
tide degradation is initiated under conditions of low
ATP and high AMP concentrations [31,32].
Superoxide dismutase and catalase activities were
signi¢cantly higher in cell lines Me5 and Me8, where-
as only superoxide dismutase increased in cell line
Me4, in which the mutant heteroplasmy was lower.
Inhibition of complexes I [15] and III [16] contributes
to mitochondrial ROS formation, while decreased
activities of complexes I and IV in the respiratory
chain [6^8] are the most common biochemical defects
associated with the 3243ACG mutation. This would
be in accord with increased ROS formation in cul-
tured myoblasts with 3243ACG and ¢ts with the
notion that catalase and superoxide dismutase
(MnSOD) [19,33] are regulated in an adaptive way,
i.e. increased ROS formation leads to increased syn-
thesis of catalase and superoxide dismutase. The fact
that superoxide dismutase activity tended to be
slightly higher in the blood cells of patients with
Fig. 3. Catalase activities in cultured myoblasts. Catalase activ-
ity was increased in myoblasts with a high degree of
3243ACG mutant heteroplasmy (Me5 and Me8), but not in
cell line Me4, with lower mutant heteroplasmy.
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the 3243ACG mutation can be explained by the
generally lower degree of mutant heteroplasmy in
blood cells than in muscle cells [3].
Our results suggest that an increased amount of
oxygen free radicals is one of the major biochemical
disturbances in the MELAS syndrome. Cybrids with
3243ACG have been shown to be more sensitive to
hydrogen peroxide-induced damage [17], and the
production of H2O2 increases in cybrids with the
same mutation at a high oxygen concentration [18].
Furthermore, we found a decrease in high energy
phosphates, and previous studies have demonstrated
decreased mitochondrial membrane potential [34,35].
Also disturbances in calcium concentration [36] have
been observed in cells with 3243ACG. Decreased
mitochondrial membrane potential, increased mito-
chondrial Ca2 concentration and increased produc-
tion of ROS is known to increase the opening of the
mitochondrial permeability transition pore (PTP)
[37]. In a reconstituted membrane system, a high
ADP concentration inhibited the adenine nucleotide
translocator to form a PTP [38]. The observations
made on 3243ACG cells [34,35], the properties of
the adenine nucleotide translocator [38] and the re-
sults obtained here suggest that the cellular homeo-
stasis is disturbed in such a way that the probability
of PTP opening may be increased. It needs to be
evaluated whether this a¡ects the adenylate compart-
mentation and their total pool size.
The pathogenic cascade evolving from the
3243ACG mutation leads to impairment of tran-
scription termination [4], a decrease in protein syn-
thesis [5] and decreased activities of the respiratory
chain complexes I and IV [6^8]. As shown here, these
defects lead to impaired ATP production, a decrease
in the total adenylate pool and increased formation
of reactive oxygen species. These pathogenic events
may partly determine the biochemical phenotype of
cells and the clinical phenotype of the patients, but,
in addition, they may trigger other cellular responses,
the roles of which in the pathogenesis of mitochon-
drial diseases remain unknown.
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